REGN · Nasdaq · CIK 0000872589

REGENERON PHARMACEUTICALS, INC.

REGENERON PHARMACEUTICALS, INC.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 15, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $14.3B and net income of $4.5B, according to its XBRL data on EDGAR. Its EDGAR record lists 45 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$14.3B
Net income, FY2025
$4.5B
Form 4 filings on record, past 12 months
45

Company overview

Legal name (as filed)
REGENERON PHARMACEUTICALS, INC.
Ticker
REGN
SEC Central Index Key (CIK)
0000872589
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
TARRYTOWN, NY
State or country of incorporation
NY
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#201 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from REGENERON PHARMACEUTICALS, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$16.1BFY2021$12.2BFY2022$13.1BFY2023$14.2BFY2024$14.3BFY2025
Net income
$8.1BFY2021$4.3BFY2022$4.0BFY2023$4.4BFY2024$4.5BFY2025
REGN annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$16.1B$12.2B$13.1B$14.2B$14.3B
Net income$8.1B$4.3B$4.0B$4.4B$4.5B
Diluted EPS$71.97$38.22$34.77$38.34$41.48
Total assets$25.4B$29.2B$33.1B$37.8B$40.6B
Cash and equivalents$2.9B$3.1B$2.7B$2.5B$3.1B

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

REGN latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 4, 202610-KAnnual report· period Dec 31, 2025Document · Index
Jul 30, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 6, 20268-KMaterial agreement; Results of operations; Other events· period Oct 1, 2026Document · Index
Apr 24, 2026DEF 14ADEFINITIVE PROXY STATEMENT· period Jun 12, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about REGENERON PHARMACEUTICALS, INC., by form type:

4 ×14144 ×98-K ×713F-HR ×210-Q ×2N-PX ×1SCHEDULE 13G ×1DEFA14A ×1DEF 14A ×1ARS ×1SCHEDULE 13G/A ×1
REGN recent filings
FiledFormWhat it isOriginal
Oct 15, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 13, 2026Document · Index
Oct 14, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 6, 20268-KMaterial agreement; Results of operations; Other events· period Oct 1, 2026Document · Index
Sep 30, 20268-KDirector or officer change· period Sep 24, 2026Document · Index
Sep 3, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 2, 2026Document · Index
Sep 3, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 3, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 2, 2026Document · Index
Sep 2, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 2, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 21, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 19, 2026Document · Index
Aug 20, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 18, 2026Document · Index
Aug 20, 2026N-PXN-PX· period Jun 30, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 10, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 10, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 7, 202613F-HRInstitutional investment manager holdings report· period Jun 30, 2026Document · Index
Jul 30, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 30, 20268-KResults of operations· period Jul 30, 2026Document · Index
Jul 7, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 2, 2026Document · Index
Jul 6, 20268-KResults of operations· period Jul 6, 2026Document · Index
Jul 2, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 17, 20268-KShareholder vote results· period Jun 12, 2026Document · Index
May 8, 202613F-HRInstitutional investment manager holdings report· period Mar 31, 2026Document · Index
May 4, 20264Statement of changes in beneficial ownership (insider trade)· period May 1, 2026Document · Index
Apr 30, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Apr 29, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 29, 20268-KResults of operations· period Apr 29, 2026Document · Index
Apr 24, 2026DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSDocument · Index
Apr 24, 2026DEF 14ADEFINITIVE PROXY STATEMENT· period Jun 12, 2026Document · Index
Apr 24, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 8, 20268-KResults of operations· period Apr 8, 2026Document · Index
Apr 3, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 1, 2026Document · Index
Mar 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 3, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 2, 2026Document · Index
Feb 23, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 19, 2026Document · Index
Feb 19, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 9, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

45 Form 4 filings appear in REGENERON PHARMACEUTICALS, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in New York

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000872589 and XBRL company facts. REGENERON PHARMACEUTICALS, INC. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.